AbbVie Inc. 3Y Operating CF Growth (per Share)

3Y Operating CF Growth (per Share) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including 3Y Operating CF Growth (per Share) growth rates and interactive chart.

Highlights and Quick Summary

  • Annual 3Y Operating CF Growth (per Share) for 2019 was 27.5% (a 17.52% increase from previous year)
  • Annual 3Y Operating CF Growth (per Share) for 2018 was 23.4% (a -42.95% decrease from previous year)
  • Annual 3Y Operating CF Growth (per Share) for 2017 was 41.02% (a 1162.15% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical 3Y Operating CF Growth (per Share) of AbbVie Inc.

Most recent 3Y Operating CF Growth (per Share)of ABBV including historical data for past 10 years.

Interactive Chart of 3Y Operating CF Growth (per Share) of AbbVie Inc.

AbbVie Inc. 3Y Operating CF Growth (per Share) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 27.5%
2018 23.4%
2017 41.02%
2016 3.25%
2015 4.84%
2014 -17.49%
2013 7.72%
2012 0.0%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.